Objectives
To provide Business Development and Licensing (BD&L) support by assessing the market landscape, product value, and resulting pricing and access potential for PRODUCT X gene therapy launch scenarios in spinal muscular atrophy (SMA).
Scope
Methodology
Conduct payer and KOL in-depth interviews (IDIs) to understand clinical value perceptions of PRODUCT X and its associated Pricing and Market Access (P&MA) opportunity across key European markets, and evaluate whether PRODUCT X represents a good investment for the client seeking to expand their cell and gene therapy portfolio.
Deliverables
- Moderator guides and research stimuli to support primary research interviews across a range of SMA expert types
- Tailored recommendations on PRODUCT X’s optimal pricing and access outcomes across EU-3 markets to support go / no-go decision-making process
Illustrative Outputs
Impact
CBP provided acquisition guidance for a novel SMA gene therapy based on pricing and market access insights in a high unmet need, pediatric, orphan space.